ストックスクリーナーアプリを入手
0.2837
0.53%
-0.0015
アフターアワーズ：
.28
-0.0037
-1.30%
IGC Pharma Inc (IGC) 最新ニュース
IGC Pharma, Inc. (IGC) Reports Q3 Loss, Tops Revenue Estimates - MSN
IGC Pharma expands CALMA trial with addition of Butler Hospital Program - Yahoo Finance
IGC Pharma Expands Phase 2 Alzheimer's Trial Site - MarketScreener
IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program - ACCESS Newswire
Major Breakthrough: IGC's Alzheimer's Agitation Drug Trial Adds Prestigious Brown University Research Site - Stock Titan
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health - PharmiWeb.com
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addi - GuruFocus
IGC Pharma announces CALMA Phase 2 trial expansion with Miami Jewish Health - TipRanks
IGC Pharma expands CALMA clinical trial - TipRanks
IGC Pharma posts promising interim data for Alzheimer’s therapy - MSN
IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances - BioSpace
IGC adds new clinical site in Canada for Alzheimer’s agitation therapy trial - Clinical Trials Arena
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences - BioSpace
IGC Pharma Adds Canadian Site to Phase 2 Trial of Investigational Alzheimer's Dementia Therapy - MarketScreener
IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida - ACCESS Newswire
IGC Pharma's Alzheimer's Drug Shows Promise: CALMA Trial Adds New Florida Site - StockTitan
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock. Raising P/T to $4.25" - ACCESS Newswire
IGC Pharma Catches Analyst Attention: $4.25 Target Set as Clinical Milestones Approach - StockTitan
IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the "Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results" - ACCESS Newswire
IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the “Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results” | FinancialContent - Financial Content
IGC Pharma's Alzheimer's Drug Trial Gets Positive Analyst Coverage - Stock Titan
IGC Pharma, Inc. (IGC) Advances AI Model to Enhance Alzheimer’s Diagnosis - Insider Monkey
12 AI Stocks Making Headlines: Latest News and Ratings - Insider Monkey
IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer's and Dementia Detection - Big News Network
Can This New AI Tool Revolutionize How Doctors Diagnose Alzheimer's Disease? - StockTitan
Ascendiant Capital Markets Issues Positive Forecast for IGC Pharma (NYSEMKT:IGC) Stock Price - Defense World
IGC Pharma expands Holiby line with ‘Longevity’, ‘Renew’ - Yahoo Finance
IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and - GuruFocus.com
IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and 'Renew'Targeting the Multi-Billion-Dollar Anti-Aging Market - Newswire
IGC Pharma's Earnings Show Major Turnaround: Net Loss Shrinks 69% While Alzheimer's Drug Shows Promise - StockTitan
IGC Pharma Reports Third Quarter Fiscal 2025 Results - ACCESS Newswire
IGC Pharma Inc. (IGC) reports earnings - Quartz
Page 3 | IGC PHARMA INC. DL -,01 Trade Ideas — FWB:IGS1 - TradingView
IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby(TM) - StreetInsider.com
IGC Pharma launches Holiby wellness brand - TipRanks
2.51%
大文字化:
|
ボリューム (24 時間):